B+
Bull case
25%
Probability
Target price
$24.50
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
GENB
Generate BiomedicinesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The strongest support is operational: GENB exited Q1 with $516.6M of cash, says that funds operations into 1H28, and has multiple 2026 pipeline milestones, including mid-2026 GB-4362 dosing and 2H26 GB-5267 dosing, while GB-0895 remains in Phase 3 severe asthma [#SEC-8K-2026-05-07].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.7.
What can break
Clinical timelines for GB-4362 and GB-5267 could slip, removing the clearest 2026 execution hooks.
Momentum
71
Value
46
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $24.50 · Bear $10.50Analysis 2026-07-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $27.00
Why
Momentum71 · Δ7d -14.1
Value46 · Δ7d 0.0
Sentiment69 · Δ7d +8.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.7.
Contradictions & invalidation
- • Clinical timelines for GB-4362 and GB-5267 could slip, removing the clearest 2026 execution hooks.
- • GB-0895 Phase 3 spending is already lifting R&D expense, so further cost growth could pressure sentiment before efficacy readouts.
- • This is still a low-revenue, loss-making clinical biopharma with rising R&D tied to GB-0895 Phase 3, widening net loss, and eventual need for additional capital for long-term operations; if 2026 dosing milestones slip, the IPO-funded runway alone may not defend the stock [#SEC-8K-2026-05-07].
Catalyst clock
2026-07-31
GB-4362 first-patient dosing expected in mid-2026
Lead driver: Sentiment · See AI snapshot
Momentum
71
9% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
-4.8
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
69
62% active weight
Current posture
7d trendImproving
Δ7d
+8.7
Δ21d
+10.4
Why this grade
Composite grade B. Momentum 70.8 / Value 46.5 / Sentiment 68.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-01. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-07-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.01B
Beta
-
Shares Out
128.35M
P/E (TTM) · Derived
-8.0
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-37.7%
EPS YoY
-73.0%
Gross Margin
-
Op Margin
-
Net Debt
-$153.31M
Current Ratio
8.30
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data